REFERENCES
1. McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg 2014;3:258-75.
2. Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD, Knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer 2014;21:153-63.
3. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K. Diagnosis and management of insulinoma. World J Gastroenterol 2013;19:829-37.
4. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma – incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991;66:711-9.
5. De Herder WW, Niederle B, Scoazec JY, Pauwels S, Klöppel G, Falconi M, Kwekkeboom DJ, Öberg K, Eriksson B, Wiedenmann B, Rindi G, O'Toole D, Ferone D and all other Frascati Consensus Conference participants. Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma. Neuroendocrinology 2006;84:183-8.
6. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2009;94:709-28.
9. Marks V, Teale JD. Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH). Clin Endocrinol (Oxf) 1998;49:491-8.